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Excess dietary fat consumption has been implicated in the development of obesity and diabetes.  
Obesity can be characterized by a disproportionate increase in fat mass compared to lean body 
mass. However, if muscle mass can be increased or maintained in obesity, this may facilitate 
weight loss by increasing the body’s overall metabolic capacity.  Historically, supplementation 
with the branched-chain amino acid leucine has been shown to increase muscle protein synthesis 
via the protein kinase mTORC1.  Recent studies suggest that supplementation with leucine also 
has the potential to reduce weight gain and fat deposition in high-fat fed, obese mice. The 
objective of this study was to determine if long-term dietary leucine supplementation prevents 
development of obesity in rats meal-fed a high fat (60%) diet.  Male, Sprague-Dawley rats 
(n=30/dietary treatment) were meal-fed (3 meals/day) either a control diet (C), control+leucine 
(CL), high-fat (HF), or high-fat+leucine (HFL) for 42 days.  HF/HFL-fed rats gained, 28 g more 
than rats fed C/CL diets (p<0.05). Plasma insulin levels in the fasted condition were not 
significant between groups; however, thirty minutes postprandial the rats supplemented with 
leucine, both on a high-fat and control diet, had significantly higher insulin levels than the 
control group (p<0.05).  Free fatty levels in the fasted condition did not differ between the 
control diet and the control diet with leucine supplementation. However, plasma free fatty acid 
levels in the fasted condition were significantly higher in the high-fat with leucine group when 
compared to the high-fat group without leucine supplementation (p<0.05).  Rats supplemented 
with leucine had significantly higher fat mass (p<0.05) and significantly lower muscle mass 
(p<0.05) compared to their respective controls.  No significant difference was detected in 4E-
BP1 and AKT phosphorylation between diets or between time points. PGC-1α expression in 
fasted conditions did not differ between leucine supplemented groups and their respective 
controls. At 30 minutes postprandial, only the control diet with leucine supplementation was 
observed to have significantly greater PGC-1α expression than the high-fat diet with leucine 
supplementation (p<0.05). Taken together, supplementation with leucine does not prevent 
development of obesity in high-fat fed rats. 
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Chapter 1: Introduction 
 More than one-third of the U.S. adult population is obese. Obesity has become an 
epidemic and major public health concern. Obesity contributes to several health risks including: 
stroke, heart disease, type-2 diabetes, and cancer [1,2]. These rank among the leading causes of 
death in the United States and may be reduced or prevented by preventing development of 
obesity.  
 Obesity can be characterized by a disproportionate increase in fat mass compared to lean 
body mass. Obesity is defined as having a body mass index of 30 or higher [1]. This increase in 
fat mass occurs when the energy balance (energy intake = energy expenditure) is altered [3]. 
When more energy is being consumed than expended weight gain, specifically fat, occurs. To 
address the disease of obesity and the health risks it poses, the issue of energy imbalance must be 
addressed. Adjusting the macronutrient composition (carbohydrates, protein, and fat) of an 
individual’s diet can aid in the treatment of obesity [3,4]. Specifically, protein content of a 
weight-loss diet is important for maintaining muscle mass and to maximize fat loss [3,5]. The 
branched-chain amino acids in protein are attributed with a muscle sparing effect in a hypo-
caloric diet [3]. Among these branched-chain amino acids, leucine is the primary activator of the 
cellular machinery associated with muscle protein synthesis [6].  
 The mammalian target of rapamycin complex 1 (mTORC1) is activated by leucine 
concentration in the cell. This complex triggers muscle protein synthesis, as well as activates 
genes responsible for fatty acid synthesis and fatty acid oxidation [3,7,8]. It may therefore be 
possible to supplement leucine to a diet in order to activate the cellular mechanisms necessary 
oxidize fat and maintain muscle in order to shift body composition to a leaner state. Additionally, 
supplementing leucine to a diet that induces obesity could delay or prevent the onset of obesity.  
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Chapter 2: Objectives 
 The objectives of this study were to: 1) determine if the supplementation of leucine to a 
high-fat diet, designed to induce obesity, would prevent or delay the onset of obesity in male, 
Sprague- Dawley rats and 2) to determine the role of dietary leucine supplementation in fat 




Chapter 3: Literature Review  
Background 
 According to the Center for Disease Control (CDC) it is currently estimated that over 
one-third of the United States adult population is obese [1].  Obesity is defined as having a body 
mass index (BMI) of 30 or higher and individuals with a BMI of 25 to 29.9 are classified as 
overweight. Obesity is not just a problem in the United States, the World Health Organization 
(WHO) estimates that worldwide obesity has double since 1980 [2]. Additionally, in 2008 it was 
estimated that 35% of adults 20 years of age and older worldwide were overweight, while 11% 
were obese [2]. Obese individuals are at an increased risk for type-II diabetes, stroke, and even 
cancer [1]. In 2008, it was estimated that the annual cost of obesity in the United States was 147 
billion dollars [1]. 
 Obesity is caused by energy imbalance and correcting this energy imbalance is essential 
for treating obesity [9]. Energy balance is achieved when the amount of energy, or kilocalories, 
that is taken in equals the amount of energy being used by an organism. When more energy is 
being taken in than is being expended, weight gain occurs. Conversely, when more energy is 
being utilized than taken in, weight-loss occurs [10].  
In a study by Layman et al. [3], twenty-four women were placed on two reduced energy 
diets (1700 kcal/day) one group consumed twice the recommended daily allowance (RDA) of 
protein (1.6g/kg of body weight/day) about a 1.4 carbohydrate to protein ratio, while the other 
group was given the standard RDA of protein(0.8g/kg of body weight/day) about a 3.5 
carbohydrate to protein ratio. It is important to also note that the fat and fiber content of both 
diets were kept the same (approximately 50g/d total fat intake and 20g/d total fiber intake, 
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respectively). These diets were calorically balanced by removing carbohydrates from the group 
that received more protein, while keeping the fat content uniform in both diets. After 10 weeks 
on the dietary interventions the group that received more protein lost more fat mass relative to 
lean mass loss than the group consuming the lower protein [3,11]. This highlights that the 
macronutrient composition (carbohydrates, protein, and fat) can alter body composition and 
subsequently health. 
 High protein diets are attributed to greater weight-loss and improved body composition 
when compared to carbohydrate diets [3,11]. It is further theorized that the branched-chain 
amino acids (BCAAs), in addition to decreased caloric intake, are the major components of high 
protein diets that generate this metabolic effect [6, 10]. There are three BCAAs: valine, 
isoleucine, and leucine. These amino acids are unique because they are the only amino acids not 
metabolized in the liver [10]. Instead, they bypass first pass metabolism and are transported to 
muscle tissue where they are metabolized [12]. This is done through the transamination of 
BCAAs which results in fuel substrates, first substrates, for energy production in the 
mitochondria and the production of alanine [10,12]. The alanine that is produced from BCAAs is 
in turn converted to glucose in the liver via the glucose-alanine cycle, which helps maintain 
blood glucose levels [10]. Stabilizing blood glucose levels can aid in controlling appetite [10]. 
 The branched-chain amino acid leucine is unique among the BCAAs because it is the 
primary amino acid that triggers protein synthesis [6]. In a study conducted by Anthony et al. [6], 
rats were fasted for 18 hours then given either saline (control), valine, isoleucine, or leucine, and 
after one hour the rats were sacrificed. Only rats treated with leucine had increased muscle 
protein synthesis [6].  Similar results were demonstrated in a study conducted by Norton et al. [5] 
where whey protein, a protein high in leucine, was shown to have the highest fractional protein 
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synthetic rate in muscle tissue, while wheat protein, a protein low in leucine, had a far lower 
fractional synthetic rate [5]. When the leucine content of the wheat protein was supplemented to 
the level of whey protein the fractional synthetic rate of the wheat protein increased to the same 
level as whey protein [5]. This demonstrates that leucine is the key amino acid in stimulating 
muscle protein synthesis.  
mTORC1 signaling and protein synthesis 
The muscle protein synthetic response is triggered when the leucine concentration inside 
the cell increases and causes activation of mTORC1 (mammalian target of rapamycin complex 1; 
Figure 1) [5,6,13].  The mammalian target of rapamycin complex 1 (mTORC1), found in every 
animal cell, incorporates both intracellular (inside the cell) and extracellular (outside the cell) 
signals to regulate cellular metabolism, growth, and the survival of the cell [13]. The activation 
of the mTORC1 complex subsequently phosphorylates a binding protein, eukaryotic translation 
initiation factor 4E-binding protein 1 (4E-BP1), which binds eukaryotic translation initiation 
factor 4E (elF4E), an initiation factor for the transcription of muscle protein synthesis; this 
binding of elF4E inactivates muscle protein synthesis [13]. When 4E-BP1 is phosphorylated it 
releases elF4, which migrates to the nucleus of the cell to form the initiation complex on the 
DNA molecule then initiates transcription of the genes related to muscle protein synthesis 
[4,14,15]. Similarly, ribosomal protein S6 kinase beta-1 (p70S6K) is activated by mTORC1 and 
phosphorylates ribosomal protein S6 when migrates the nucleus to initiate transcription of 
protein synthetic genes. This protein synthetic response is essential in maintaining muscle mass, 
which, in turn, helps to maintain energy metabolism. As muscle mass decreases metabolic 
activity in the body will decrease [4,14,15,16]. Alternatively, some studies have suggested that a 
reduction in proteolysis, the breakdown of protein, could be a contributing cause of muscle mass 
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regulation in long-term leucine supplementation studies. In a study by Sugawara et al.[17], rats 
were fed a low-protein diet and supplemented with 1.5% leucine in the drinking water. A 
suppression effect on protein degradation was observed in the leucine supplemented group [17].  
However, this suppression of protein degradation is less documented than the protein synthetic 
response to leucine supplementation. Taken together leucine supplementation may play a role in 
both the reduction of protein degradation and the stimulation of protein synthesis [4,5,14-19]. 
  
 















Figure 1. Leucine acts through the mTORC1 signaling pathway to stimulate protein synthesis.  Adapted from Laplante M. and D. M. 
Sabatini [13]. As the concentration of leucine inside the cell increases mTORC1 is phosphorylated leading to the phosphorylation of 
4E-BP1 and P70S6K. The phosphorylation of these triggers protein synthesis inside the cell. Additionally, [13]. Insulin Receptor 
Substrate-1 (IRS-1) is activated by insulin triggering a signaling cascade that phosphorylates Akt this phosphorylation stimulates 
inhibition of mTORC1 and also triggers Glut-4 to translocate to the cell membrane to facilitate glucose transport. Leucine can 










Figure 2. The potential role of leucine in regulation of gene transcription via the mTOR pathway.  Adapted from Laplante M. and D. 
M. Sabatini continued [13]. As the concentration of leucine inside the cell increases mTORC1 is phosphorylated and then translocates 
to the nucleus where it signals the transcription of genes related to mitochondrial biogenesis (PGC-1α) and lipid synthesis (PPARγ). 
Leucine can stimulate the phosphorylation of mTORC1 and subsequently P70S6K, this can inhibit IRS-1 and disrupt the inhibition of 




The role of leucine in glycemic response  
 Leucine stimulates the release of insulin from the pancreas and may also modulate the 
uptake of insulin into both skeletal muscle tissue and adipose tissue [20]. Insulin can stimulate 
muscle protein synthesis through the insulin-PI3K pathway, this pathway causes downstream 
activation of the mTORC1 pathway. However, phosphorylation targets downstream of mTORC1 
can affect insulin sensitivity by a feedback loop which phosphorylates insulin receptor substrate 
1 (IRS1) [20]. If the cell becomes insensitive to insulin, glucose uptake is restricted (Figure 1), 
however, if insulin sensitivity increases then more glucose is taken up by the cell and used as a 
metabolic fuel source [20,21]. Glucose levels, as well as insulin, may be effected by leucine 
supplementation. In a study conducted by Binder et al. [8], mice were fed a high-fat diet (60% 
fat) or standard chow for 8 weeks. At 8 weeks, they were returned to a standard chow diet with 
standard water or supplemented with 1.5% leucine (wt./vol.) in the drinking water for 21 weeks. 
This study found that leucine supplementation improved glucose tolerance in both previously 
high-fat fed and standard fed groups. However, it is important to note that leucine 
supplementation in combination with the conversion to standard chow from a high-fat diet had a 
greater improvement in glucose levels. Additionally, insulin sensitivity improved with the 
exposure to standard chow but leucine did not stimulate any further effect [8]. A similar study 
adding leucine to the drinking water was conducted, however this study supplemented leucine in 
the drinking water while mice were being fed a high-fat diet for 17 weeks [7]. In standard chow 
conditions leucine supplementation had no effect on glucose or insulin tolerance. However, 
fasting plasma insulin levels were lower in mice fed high-fat with leucine supplemented in the 




with leucine in the drinking water showed a greater sensitivity to insulin than the high-fat fed 
group with standard water [7].  
In contrast, leucine supplementation has also been shown to have no effect on glucose 
tolerance, plasma glucose level, and insulin glucose levels in non-obese mice supplemented with 
leucine to a diet containing adequate protein levels [22]. A study by Li et al. [14], was conducted 
by supplementing leucine to the drinking water high-fat fed and standard chow fed rats. This 
study supplemented leucine to the drinking water in 4 different amounts 0%, 1.5%, 3.0%, and 
4.5% leucine for 24 weeks. Leucine supplementation had no effect on fasting glucose levels for 
any of the groups. The high-fat diet induced an increase in fasting insulin levels, this was 
attenuated by leucine supplementation, regardless of concentration supplemented. Additionally, 
the decrease in insulin sensitivity associated with a high-fat diet was rescued by leucine 
supplementation regardless of leucine concentration. In this study, no additional insulin 
sensitivity was observed in rats fed a standard chow diet [14].  
Mechanistically, in high-fat fed rats Akt and mTOR phosphorylation increased at the 
basal level compared to controls. As a result, when insulin is present in animals fed a normal diet 
an increase in the phosphorylation of Akt occurs, however, when insulin is present in a high-fat 
diet this increase phosphorylation does not occur, the result is insulin resistance [18]. Long-term 
leucine supplementation enhances insulin stimulated phosphorylation of Akt and mTOR in 
muscle, liver, and adipose tissue. Also, insulin receptor substrate 1 (IRS1) phosphorylation has 
been associated with insulin resistance, but the phosphorylation of IRS1 may be associated with 
insulin sensitivity [18].  
Some studies suggest that chronic leucine supplementation initiates a feedback loop from 




the phosphorylation of IRS1, subsequently improving insulin sensitivity [18,23]. A possible 
explanation for this difference in observations could be related to the dose of leucine. Li et al. 
[18] identify that acute high levels of leucine could trigger insulin resistance, while small dose 
such as the 1.5% leucine in water could promote insulin sensitivity. Therefore, insulin sensitivity 
through the IRS1/AKT/mTOR/S6k1pathway may be dose dependent. Taken together 
supplementation of leucine to animals fed a high-fat diet tends may improve insulin sensitivity. 
[18,23]. However, in another study by Newgard et al. [21] high-fat fed rats were supplemented 
with BCAAs, in the chow, and showed the same insulin resistance as high-fat fed rats. A chronic 
phosphorylation of the mTORC1 pathway and IRS-1 was also observed suggesting a possible 
resistance to insulin [21]. Considering all arguments, it is not completely clear why insulin 
sensitivity is influenced one way or another with leucine supplemented in high-fat diets 
[7,8,14,18,22].  
Leucine supplementation and body composition 
 Body composition is key in ensuring health [1]. Muscle is a metabolic tissue, the more 
muscle tissue an organism has the more energy can be expended. Supplementing leucine to 
facilitate a change in body composition has shown different effects. In a study by Li et al.[14], 
leucine was supplemented to the drinking water of rats fed either a high-fat diet or normal chow 
diet in 4 different amounts 0%, 1.5%, 3.0%, and 4.5% leucine for 24 weeks. The authors 
observed that rats fed a high-fat diet supplemented with leucine had a significantly higher body 
weight than all other groups, including the high-fat control. This was also accompanied by an 
increase in fat mass in leucine supplemented high-fat groups [14]. In contrast, a similar study 
supplementing 1.5% leucine in the drinking water of mice observed a significant reduction in the 




mice. Additionally, significant reduction of both visceral and subcutaneous body fat was 
observed in the high-fat fed mice supplemented with leucine when compared to the high-fat 
control mice [18].  
The difference could be due to the different species or diet interventions used in the 
experiments. Leucine supplemented to a normal diet does not seem to elicit a change in body 
composition [22]. Noatsch et al. [22], observed this when mice were fed an adequate protein diet 
supplemented with leucine (4.5g/100g of diet). The authors observed no significant changes in 
body weight, energy expenditure, or body composition as a result of leucine supplementation 
[22]. Interestingly, a study conducted by Binder et al. [7] supplementing 1.5% leucine to the 
drinking water of mice fed a high-fat diet for 17 weeks in an effort to prevent the effects of a 
high-fat diet. This study showed a significant reduction in body weight and fat mass in the 
leucine supplemented (~55.6mg/d) high-fat fed mice when compared to the high-fat control 
group, however, no change was observed in mice fed a normal diet supplemented with leucine 
(~74.5mg/d) compared to a normal diet [7]. Taken together leucine supplementation may have a 
positive effect on body composition depending on the dose, species, and method of 
administration [8,22]. 
Leucine and Fatty acid metabolism  
Leucine can be metabolized in muscle cells to produce acetyl CoA, a substrate for 
mitochondrial oxidation to produce energy.  This acetyl CoA entry point into oxidative 
metabolism is also the same entry point by which fatty acids are utilized by the mitochondria for 
fuel inside the cell [24]. Leucine supplementation may be linked to fatty acid oxidation [8]. In a 
study conducted by Binder et al. [8], mice were fed a high-fat diet or standard chow for 8 weeks, 




(wt./vol.) in the drinking water for 21 weeks. Indirect calorimetry was used to determine the 
respiratory quotient, a measurement used to determine the primary source of fuels being used for 
energy in real time, of the mice in this study and mice supplemented with leucine had a lower 
respiratory quotient, indicating an increased usage of fatty acids [8]. It is important to note that 
no changes in the expression of genes related to fatty acid oxidation were observed in muscle 
tissue. Similar results were observed in another study when 1.5% leucine was supplemented in 
the water of mice fed a high-fat diet, no changes were observed in gene expression related to 
fatty acid oxidation [7]. However, in a study by Li et al.[18], leucine supplemented in the 
drinking water of high-fat fed mice has be shown to have an effect on fatty acid metabolism in 
skeletal muscle tissue. In this particular study the authors found an increase in sirtuin 1 (SIRT1), 
a protein associated with metabolic regulation and tolerance of oxidative stress, protein and gene 
expression as well as an increase fatty acid oxidation gene expression in the skeletal muscle of 
high-fat fed mice supplemented with leucine in the drinking water [8]. It thought that leucine 
supplementation stimulates the activation of AMP-activated protein kinase (AMPK) which in 
turn simulates SIRT1 signaling. Also, a decrease in the acetylation of peroxisome proliferator-
activated receptor gamma coactivator 1-alpha (PGC1α), a gene marker for mitochondrial 
biogenesis, and forkhead box O1 (FoxO1), a gene marker for negative effects on adipogenesis, 
was observed. The deacetylation of these PGC1α and FoxO1 allow genes associated with 
mitochondrial biogenesis and genes controlling energy homeostasis to be transcribed [18]. Taken 
together leucine supplementation has been shown to activate genes associated with fatty acid 
transport and oxidation in adipose tissue. However, the activation of proteins controlling fatty 





It is widely accepted that leucine supplementation stimulates the cellular pathway for 
muscle protein synthesis. The possibility of supplementing leucine in a high-fat diet to prevent 
obesity has not been clearly established. Therefore the objectives in this study were to: 1) 
determine if the supplementation of leucine to a high-fat diet, designed to induce obesity, would 
prevent or delay the onset of obesity in male Sprague Dawley rats and 2) to determine the role of 
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Chapter 4: Specific Aims 
AIM 1: Determine if the supplementation of leucine to a high-fat diet would prevent or 
delay the onset of obesity.  
 Challenge: To assess the obesigenic effects of a high-fat diet with leucine 
supplementation. 
 Approach: Animals were weighed daily to track weight gain and body composition was 
determined postmortem. 
 Impact: These measurements were used to determine the body composition of the 
animals in order to establish the consequences of leucine supplementation to a high-fat diet. 
AIM 2: Determine the metabolic effects of leucine supplementation on a high-fat diet to 
prevent or delay the onset of obesity. 
 Challenge: To determine if leucine supplementation could stimulate the use of fatty acids 
as an oxidative fuel source. 
 Approach: Plasma glucose, insulin, and free fatty acids were measured at a fasted time 
point, 30 minutes postprandial, and 90 minutes postprandial to determine metabolic response to 
leucine supplementation. 
 Impact: These measurements were used to determine if leucine supplementation changes 
the glycemic response to a high-fat as well as the free fatty acid content. 
AIM 3: Determine the mTORC1 signaling response to leucine supplementation on a high-




 Challenge: To determine the signaling cascade leading to muscle protein synthesis and 
expression of gene related to fatty acid oxidation via the mTORC1 pathway. 
 Approach: Phosphorylation of the downstream marker 4E-BP1 was measured to 
determine protein synthetic response to supplementation. PPARγ and PGC-1α gene expression 
was measured to determine fatty acid oxidative response, in the mTORC1 pathway. 
 Impact: These measurements will determine the effect leucine supplementation to a 






Chapter 5: Methodology  
Animals  
 Six-week old male, Sprague-Dawley rats were divided into four treatment groups (n=30 
per treatment group) totaling 120 rats. Animals were either fed a control diet (Control), control 
diet supplemented with leucine (Control+Leu), high-fat diet (High-fat), or a high-fat diet 
supplemented with leucine (High-fat+Leu).   
 All animals were housed individually at the University of Arkansas, Central Laboratory 
Animal Facility (CLAF). Rooms were maintained at 22oC with a reversed light/dark cycle 
(12:12). All animals were weighed daily and all handling and treatment was in compliance with 
IACUC standards. 
Diet design 
 Control diets were based on AIN-93G diet (Harlan Laboratories Inc., Houston, TX) and 
high-fat diets were based on a Harlan 60% fat diet (Harlan Laboratories Inc., Houston, TX). 
Thirty-two grams of leucine per kilogram of diet was supplemented into Control+Leu and High-
fat+Leu diets, while 32g of glycine per kg of diet was supplemented into Control and High-fat 
diets. The equal amounts of each amino acid were added to ensure nitrogen balance between 




Table 2. Diet composition
 
Composition of diets shows the ingredients and amounts (g/kg) used when mixing the different 
diets. Cornstarch was removed and lard was added to High-fat diets. Thirty-two grams of 
leucine was added to the leucine supplemented diets and 32g of glycine was added to non-






 Animals were meal-fed to mimic human eating behavior, so as to model responses for 
human applications. Animals were fed three meals per day: breakfast, lunch, and dinner. 
Breakfast was an isocaloric (16.8 kcal; 4g control, 3.1g high-fat) feeding in order to assess 
postprandial responses to diets and animals were allowed 20 minutes to eat their meal. Lunch 
and dinner were ad libitum access to their designated diet. Animals were allotted 1 hour to eat 
their meals at lunch and dinner. Food bowls were weighed prior to and after feeding to assess 
food intake and all uneaten chow was discarded after weighing. Animals were fed their 








Figure 3. Meal-feeding design
 
A pictorial representation of the meal feeding designed in the study. Breakfast was isocaloric, while lunch and dinner were ad libitum. 





 After 6 weeks all animals were sacrificed by decapitation. Animals were sacrificed at one 
of three time points: 0 minutes (fasted), 30 minutes postprandial, or 90 minutes postprandial. 
This was done to observe any changes that may occur as a result of feeding. Blood was 
immediately collected and plasma extracted, then snap frozen in liquid nitrogen. The 
gastrocnemius, soleus, and plantaris muscles were extracted and snap frozen in liquid nitrogen. 
The liver and epididymal fat were also extracted and snap frozen in liquid nitrogen. All samples 
were stored in -80oC freezer for future analysis. All muscle tissue, liver, and epididymal fat were 
weighed and recorded prior to freezing. 
Plasma glucose, insulin, and free fatty acids 
 Plasma glucose was analyzed using a glucose oxidiase colorimetric assay kit (Cayman, 
Ann Arbor, MI). Insulin was analyzed using a colorimetric kit (ALPCO, Salem, NH). Plasma 
free fatty acids were analyzed using an enzymatic fluorescence kit (Cayman, Ann Arbor, MI). 
Assays were done in duplicate in accordance with manufacturer instructions and all microplates 
were read using a HT-Synergy microplate reader (BioTek, Winooski, VT). 
Tissue processing and sample preparation 
 All tissues powdered using a mortar and pestle in liquid nitrogen. Powdered tissue was 
then stored at -80oC. Powdered tissue samples were used for all future protein and gene 
expression analysis.  
 For protein sample preparation samples were homogenized with a Polytron handheld 
homogenizer, in 7 volumes of homogenization buffer (20mM HEPES, 2 mM EGTA, 50 mM 




benzamidine, 0.5 mM sodium vanadate, and 10μl/ml protease inhibitor cocktail (Sigma-Aldrich, 
St. Louis MO)). Homogenate was then spun down at 4oC in a centrifuge at 10,000 rpm. The 
supernatant layer was collected and stored at -80oC for western blotting analysis. 
 For RNA sample preparation samples were homogenized with Polytron handheld 
homogenizer, in homogenization buffer from RNA extraction kit (Norgen, ON, Canada), then 
centrifuged at 10,000 RPM while chilled at 4oC. Supernatant was pipetted off and used for RNA 
extraction. RNA was extracted using an RNA extraction kit (Norgen, ON, Canada) in accordance 
with the manufacturer instructions. RNA was stored at -80oC for future gene expression analysis. 
Western blotting analysis 
 Bio-rad western blotting apparatus was used for all western blotting analysis. Pre-cast 
10% and 12% SDS-Page gels (Bio-rad, Hercules, CA) were used and gels were all ran at 200V 
for 45 minutes and transferred to blotting paper (Bio-rad, Hercules, CA) at 100V for 1 hour. 
Wester C protein plus standard with conjugate (Bio-rad, Hercules, CA) was used on all gels to 
determine molecular weight. All blots were placed on a rocker and incubated in 5% milk in 
TBST (Tris-Buffered Saline and Tween) for 1 hour. Primary antibodies were diluted 1:1000 in 
TBST and poured over blots, then placed on a rocker and incubated overnight at 4oC. Antibodies 
used were p-Akt, Akt, p-4E-BP1 (ser65), and 4E-BP1 (Cell Signaling, Beverly, MA), as well as 
P70S6K (Bethyl, Montgomery, TX). The secondary antibody was diluted 1:1000 in TBST and 
poured over blot, then incubated at room temperature on a rocker for 1 hour, the secondary 
antibody used was anti-rabbit (Cell Signaling, Beverly, MA). All blots were rocked in 
electrochemiluminescence (ECL) solution for 2 minutes at room temperature prior to developing 
in Flourochem M imager (Protein Simple, Santa Clara, CA). Densitometry was determined using 




Gene expression analysis  
 RNA was converted to cDNA via RNA to cDNA conversion kit (Quanta, Gaithersburg, 
MD). Conversion was done in accordance with manufacturer instruction in a Lightcycler 480 
system (Roche, Basal Switzerland). All cDNA was stored in -20oC freezer for future analysis. 
SYBER green master mix (Quanta, Gaithersburg, MD) was used as the reporter dye for both 
PGC-1α, PPARγ (Table 2), and 18s. All samples and controls were run in duplicate and ran in 
RT-PCR machine (ABI Systems, Grand Island, NY). All gene expression data was calculate 
using the ΔΔCT method for RT-PCR. 
Statistical Analysis 
 Weight data was all compared using a one-way ANOVA and the means from the 4 
treatment groups were used to generate graphs. Plasma glucose and insulin data was graphed 
using the means of the each treatment group at each time point, a two-way ANOVA was 
performed in order to observe any interaction between diet and time point. A two-way ANOVA 
was also used when comparing the protein and gene expression data across treatment groups and 
time points. Multiple t-tests were used to determine significance between groups within each 
time point, with Sidak-Bonferroni method for adjustment. All statistical calculations were 
performed by statistical software (GraphPad) and the graphs of the data were also made in 





Table 3. Primer sequences 
Gene Primer sequence 
PGC-1α Forward: 5'- TGA AGA GCG CCG TGT 
GAT T -3’ 
PGC-1α Reverse: 5'- TTC TGT CCG CGT TGT GTC 
A -3' 
PPARγ Forward 5'- CCC ACC AAC TTC GGA ATC 
AG -3' 
PPARγ Reverse: 5'- GGA ATG GGA GTG GTC 
ATC CA -3’ 
 
Table 3 shows the PGC-1α and PPARγ primer sequences used for RT-PCR in this experiment. 











Chapter 6: Results 
Body Composition 
 At the end of the study rats fed a high-fat diet or high-fat diet with leucine experienced 
higher body weights when compared to rats fed a control diet or control diet with leucine 
(p<0.05). There was no difference in body weights between the leucine supplemented groups and 
their respective controls (p<0.05, Figure 4A). 
 Weight gain was also tracked over the course of the study. After two weeks animals fed 
the high-fat diets started to gain a slight but significant amount of weight when compared to the 
control fed groups (p<0.05). Animals fed the high-fat diets had a significantly higher body 
weight compared to the control fed groups (Figure 4B). 
 There was a reduction in the muscle weights of rats supplemented with leucine when 
compared to their respective controls. Rats fed a control diet supplemented with leucine showed 
a reduced muscle weight when compared with rats fed a control diet without leucine 
supplementation (p<0.05). Similarly, rats fed a high-fat diet supplemented with leucine had 
significantly lower muscle weight when compared to rats fed a high-fat diet without leucine 
(p<0.05). Additionally, rats fed a high-fat diet had the highest muscle weight across all the 
groups, and rats fed a control group with leucine had the lowest muscle weight across all the 
groups (p<0.05, Figure 5A). 
 Significant differences in fat mass were also detected. We observed a significant increase 
in the fat mass of rats fed control diet and supplemented with leucine over rats fed a control diet 
without leucine supplementation (p<0.05). Rats fed a high-fat diet supplemented with leucine 




animals that were fed a high-fat diet, with or without leucine supplementation, had a significantly 
higher fat mass than animals fed a control diet (p<0.05, Figure 5B).   
Western Blotting Analysis 
 In the fasted state, 4E-BP1 phosphorylation trended higher in the control diet without 
leucine supplementation than the control diet with leucine supplementation, the high-fat diet 
without leucine supplementation, and the high-fat diet with leucine supplementation (p<0.097, 
p<0.087, p<0.053; respectively). No differences were detected at 30 minutes postprandial or 90 
minutes postprandial (Figure 6). 
 No significant differences were detected in Akt phosphorylation between groups or time 
points (Figure 7). 
Gene Expression 
 PGC-1α expression in fasted conditions, 30 minutes postprandial, and 90 minutes 
postprandial did not differ between leucine supplemented groups and their respective controls. 
No notable interactions between time points and diets were observed were observed in this study 
(p<0.05, Table 4). 
 PPAR-γ expression in fasted conditions did not differ significantly between any of the 
groups. At 30 minutes postprandial, no significant differences were observed; however, the high-
fat diet with leucine trended lower than the high-fat diet without leucine (p<0.08). Additionally, 
the high-fat diet with leucine trended lower than the control diet with leucine (p<0.09). At 90 






Figure 4. Total body weights and weight gain over time 
 
Data expressed as means + SEM. Different letters indicate significance, p<0.05. (A) 
Shows the Total body weights from each group. Total body weights of rats taken immediately 
before sacrifice, but prior to breakfast on sacrifice day. High-fat fed groups experienced a 
higher total body weight when compared to control diets (n=30 per treatment group). (B) Tracks 
the weight gain of the rats in each diet group per week until the sacrifice day, annotated by week 
7. On sacrifice day animals fed a high-fat diet experience significantly higher weight gain when 





Figure 5. Total muscle weight and fat weight  
 
 Data expressed as means + SEM. Different letters indicate significance, p<0.05. (A) 
Total muscle wet weight was taken upon muscle extraction (n=30 per treatment group). Leucine 
supplemented groups experience a lower total muscle weight when compared to their respective 
controls (p<0.05). (B) Epididymal fat weight was taken upon fat tissue extraction (n=30 per 
treatment group). Leucine supplemented groups experience a higher total gain in fat weight 





Figure 6. 4E-BP1 phosphorylation 
 
 Data expressed as means + SEM. Phosphorylation of 4E-BP1 express in a ratio of 
phosphorylated 4E-BP1 to total 4E-BP1(20 kDa). Changes in 4E-BP1 phosphorylation were 
observed in response to an isocaloric meal. Measurements were taken at fasted (0), 30 minutes 





Figure 7. Akt phosphorylation 
 
Data expressed as means + SEM. Phosphorylation of Akt express in a ratio of 
phosphorylated Akt to total Akt (62 kDA). Changes in Akt phosphorylation were observed in 
response to an isocaloric meal. Measurements were taken at fasted (0), 30 minutes postprandial, 





Table 4. PGC-1α and PPARγ gene expression 
 
 Data expressed as means + SEM. PGC-1α gene expression was observed in response to 
an isocaloric meal as a maker for mitochondrial biogenesis. Measurements were taken at fasted 
(0), 30 minutes postprandial, and 90 minutes postprandial (n=5 per group). A two-way ANOVA 
was used to determine an interaction across and within time points. . PPARγ gene expression 
was observed in response to an isocaloric meal as a measure of lipogenesis. Measurements were 






Plasma Insulin, Glucose and Free Fatty Acids 
 Plasma insulin levels in the fasted condition were not significant between groups; 
however, both the high-fat and high-fat with leucine supplementation trended higher than the 
control diet (p<0.08) in the fasted state. At 30 minutes postprandial the rats supplemented with 
leucine, both on a high-fat and control diet, had significantly higher insulin levels than the 
control group (p<0.05). However, no other significant differences were observed at the 30 
minute time point. At 90 minutes postprandial no significance between any of the groups was 
observed. However, a possible relationship was observed between the control group and the 
high-fat with leucine supplementation group (p<0.11, Figure 8). 
 Glucose levels in the fasted condition did not differ between groups. At 30 minutes 
postprandial and at 90 minutes postprandial no differences were observed between the groups 
(Figure 9). 
 Free fatty levels in the fasted condition did not differ between the control diet and the 
control diet with leucine supplementation. However, plasma free fatty acid levels in the fasted 
condition were significantly higher in the high-fat with leucine group when compared to the 
high-fat group without leucine supplementation (p<0.05). Although not significant, rats fed a 
control diet with leucine did trend higher in fasting conditions (p<0.10) when compared to the 
high-fat fed group. At 30 minutes postprandial, we observed no difference in plasma free fatty 
acid levels between groups supplemented with leucine and their respective controls. However, 
both the control diet and the control diet with leucine had significantly lower plasma free fatty 
acid level when compared to the high-fat fed group without leucine supplementation (p<0.05). 
Only the control diet with leucine supplementation was significantly lower at the 30 minute time 




without leucine supplementation showed a trend of being lower (p<0.08). At 90 minutes 
postprandial, again we observed no difference in plasma free fatty acid levels between groups 
supplemented with leucine and their respective controls. However, we observed a significant 
decrease in plasma free fatty acids levels of rats fed a control diet or control diet supplemented 
with leucine, when compare to rats fed a high-fat diet without leucine supplementation (p<0.05). 
While only the control diet without leucine supplementation had significantly lower plasma free 
fatty acid levels when compared to the high-fat diet with leucine supplementation group, a trend 
was observed between the control diet with leucine supplementation and high-fat diet with 





Figure 8. Plasma insulin levels 
 
 Data expressed as means + SEM. Plasma insulin levels observed in response to an 
isocaloric meal. Measurements were taken at fasted (0), 30 minutes postprandial, and 90 
minutes postprandial (n=10 per group). Two-way ANOVA was used within each time point and 





Figure 9. Plasma glucose levels 
 
 Data expressed as means + SEM. Plasma glucose levels observed in response to an 
isocaloric meal. Measurements were taken at fasted (0), 30 minutes postprandial, and 90 
minutes postprandial (n=10 per group). Two-way ANOVA was used within each time point and 





Figure 10. Plasma free fatty acid levels 
 
 Data expressed as means + SEM. Plasma Free Fatty acid levels observed in response to 
an isocaloric meal. Measurements were taken at fasted (0), 30 minutes postprandial, and 90 
minutes postprandial (n=10 per group). A two-way ANOVA was used to determine an 
interaction across and within time points, and mutiple t-tests were used within each time point to 





Chapter 7: Discussion 
 The aim of the current study was to examine the ability of preventing the onset of diet-
induced obesity by supplementing the branched-chain amino acid leucine to a high-fat diet in 
male, Sprague-Dawley rats. To our knowledge, this is the first study to look at leucine’s ability 
to prevent, rather than treat, obesity. This study is unique, because, contradictory to current 
literature, this study demonstrated that male, Sprague-Dawley rats fed a high-fat diet experienced 
higher levels of weight gain when compared to a control diet. In addition, leucine 
supplementation to both the control diet and high-fat diet increased adiposity levels above that of 
the diet alone. When total muscle weight was compared across the diets we observed a slight but 
significant drop in the muscle mass of rats supplemented with leucine when compared to their 
respective controls. This study is not the first to show that leucine supplementation can increase 
adiposity above that of a high-fat diet alone [14]. Li et al. [14], showed this when leucine was 
supplemented to a high-fat diet via water, this resulted in an increase in body weight, primarily 
due to fat mass increase [14]. Additionally, another study has shown that BCAA 
supplementation in the food of high-fat fed rats increased weight-gain and adiposity [21]. This is 
thought to be as a result of BCAA metabolites competing for oxidation with fatty acid 
metabolites [21]. 
The plasma insulin levels in rats supplemented with leucine were notably higher than the 
control diet at 30 minutes postprandial. This could be due to the leucine stimulating insulin 
release from the pancreas. Although no significance was observed, we did observe a trend in 
both the high-fat diets as having higher plasma insulin levels in the fasted state when compared 
to the control diet. Although, plasma insulin levels stayed elevated after 90 minutes postprandial 




et al.[22], where at 30 minutes postprandial insulin levels spike due to leucine supplementation 
and stay elevated at 60 minutes [22]. 
Plasma glucose levels increased in response to feeding and subsequently return to basal 
level. It is of note that the control diet without leucine supplementation trended lower than the 
other diets 30 minutes after feeding. This could indicate that the leucine supplemented in our 
study may have elicited a response similar to that of a high-fat diet. A similar observation was 
made in a study by Newgard et al [21], when BCAAs were supplemented to a high-fat diet. 
However, it has been show that leucine supplementation can lower blood glucose levels with 
supplemented to a normal diet [22] and in a high-fat diet [14]. These effects were not observed in 
this study. 
While plasma free fatty acid levels did differ significantly between all the groups in the 
fasted state. In response to feeding, at 30 minutes postprandial we noticed a significant drop in 
plasma free fatty acid levels in the control diet group when compared to the high-fat diet groups. 
This pattern perpetuated at 90 minutes postprandial, further illustrating that mobilization of free 
fatty acids decrease in response to meal-feeding. The high-fat groups had consistently higher 
levels over the control diets in response to feeding probably due to the 60% fat content of the 
high-fat diet. Although, it seems that in the fasted state there could be more circulating free fatty 
acids in leucine supplemented groups. It is unclear if this mobilization is done for the storage of 
fatty acids in adipose tissue or for the oxidation of fatty acids in muscle tissue. Newgard et al 
[21], suggests that fat accumulation is in large part due to BCAAs metabolites competing for 
oxidation with fatty acids in the mitochondria of muscle tissue [21]. It is unclear if this is 




this is the reason we are seeing an increase in weight accumulation as a result of leucine 
supplementation. 
 It has been well established that leucine activates the mTORC1 pathway and activates 
muscle protein synthesis. However, in this study we did not observe the phosphorylation of the 
downstream target of mTORC1, 4E-BP1. We only observed a trend at the fasted time point 
showing the control diet without leucine supplementation had higher phosphorylation. No other 
changes in 4E-BP1 were shown as a result of leucine supplementation. Which could indicate that 
the concentration of leucine within the cell never reached a sufficient level to activate mTORC1. 
This could be due to the metabolism of the leucine as an oxidative fuel source subsequently not 
causing a high enough concentration increase within the cell. However, chronic phosphorylation 
of IRS-1 and mTORC1 could have also occurred in the cell causing insulin resistance and 
increasing the fat mass of leucine supplemented groups [4,5,13-19].  
We further observed that PGC-1α expression in the control diet with leucine was 
signifcantly higher than the high-fat diet with leucine group at 30 minutes postprandial. This 
could indicate that leucine supplementation stimulates the activation of PGC-1α through the 
mTORC1 pathway is occurring, but is blunted in the presence of a high-fat diet, however this 
effect seems to drop to basal levels at 90 minutes postprandial. It is unclear why a similar trend 
was not observed in the high-fat fed group with leucine.  
PGC-1α expression has been shown to increase with leucine supplementation in the water 
and have a positive effect on delaying obesity [18]. In the current, we observed no significant 
increase in PGC-1α expression was detected that could be solely attributed to leucine 




fashion. This method of delivery and timing could be a contributing factor in the effectiveness of 
leucine supplementation [7,18]. 
It is interesting to note that while no significant changes were observed in PPARγ gene 
expression across any of the time points, we did observe a trend at in the PPARγ expression in 
rats fed a high-fat diet with leucine. We observed a decreased trend in the PPARγ expression in 
this group. This, is interesting since this group seemed to gain the most weight as a result of a 
high-fat diet with leucine supplementation. Although we observed no changes PPARγ, it is 
activate through the mTORC1 pathway [13]. However, it is not uncommon to see no response in 
PPAR activation [8,21] 
It is important to note that the age of the rats in our study was 6 weeks old. This could be 
a source of some discrepancies, since other studies usually start at 8 weeks with a rat model and 
supplement for longer than 6 weeks [14]. This could be a reason for some differences we see. 
However, the goal of this study was to observe the onset of obesity which usually happens 
around 6 weeks of supplementation [14]. Additionally, we supplemented leucine in the chow and 
not the drinking water. This method of supplementation is not as common as supplementing 
leucine in the drinking water, but has been shown to be an effective means of delivering leucine 
[22, 26-30] 
In conclusion, we have demonstrated that the supplementation of leucine to a high-fat 
diet does not prevent the onset of diet-induced obesity in rats fed a high-fat diet. In fact, groups 
supplemented with leucine experience higher levels of adiposity than their respective controls. 
While the mechanisms underlying this are still unclear we have examined targets downstream in 
the mTORC1 signaling pathway to determine if this pathway has been stimulate. However, we 
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1. Reconstitute Primers:  xx nm X 10 = xx ul of H2O (pure and autoclaved water) 
2. Dilute primers to “Working Primer Solutions”: Add 20ul of Reconstituted Primer to 180ul of H2O 
(pure and autoclaved water); yielding a total volume of 200ul of Working Primer Solution. Ex. 20ul 
of Reconstituted Primer + 180ul of H2O (pure and/or autoclaved water) = 200ul Working Primer 
Solution 
3. Next, make “Master mix” by adding : n X 10ul of sybergreen mix =  xx ul of sybergreen mix 
          n X 1ul of Reconstitute Primer F (forward)= xx ul of primer  
          n X 1ul of Reconstitute Primer R (Reverse)= xx ul of primer 
          n X 8ul of H20 (pure and autoclaved) = xx ul of H20 
n = number of samples or wells per gene (e.g. FAS, ACC, 18s) always 
make a little more than you need. So, if n=50 make n=55. 
4. Add 5ul of Diluted cDNA sample in to well. NOTE: if you have not diluted the samples from your 
cDNA plate, do so now. Diluting cDNA: Label micro centrifuge tube and place 18-20ul of sample in 
tube with 180ul of water. IMPORTANT: Ensure you have extracted the same amount of cDNA from 
each sample for dilution. EX. If you only extract 18ul from one well then get 18ul from all the wells. 
5. Next add 20ul of primer specific Master mix (e.g. FAS, ACC, 18s) to desired wells. 
6. Place plastic cover over plate and seal thoroughly, then centrifuge to pull contents of each well to 
the bottom of the well. 
7. Place in PCR machine and run desired program depending on primers. 
    
Example plate layout 
in duplicate         
               
   1 2 3 4 5 6 7 8 9 10 11 12  
 A S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6  
 B S7 S7 S8 S8 S9 S9 S10 S10 S11 S11 S12 S12  
 C S13 S13 S14 S14 S15 S15 S16 S16 S17 S17 S18 S18  
 D S19 S19 S20 S20 S21 S21 S22 S22 S23 S23 S24 S24  
   E S1 S1 S2 S2 S3 S3 S4 S4 S5 S5 S6 S6  
 F S7 S7 S8 S8 S9 S9 S10 S10 S11 S11 S12 S12  
 G S13 S13 S14 S14 S15 S15 S16 S16 S17 S17 S18 S18  
 H S19 S19 S20 S20 S21 S21 S22 S22 S23 S23 S24 S24  
               
 
S#= SAMPLE 
NUMBER             
   
Housekeeping/reference gene 
(e.g. 18s, GAPDH)          
   
Target gene (e.g. FAS, 






Run Parameters (may vary; this is base on FAS and 18s primers; 58oC could vary to 60oC): 
Initial hold- 50oC for 2 minutes 
        95oC for 10 minutes 
40 cycles of- 95oC for 15 SECONDS 






Western Blotting Protocol 
1. Set heat block to 98oC and wait for heat block to come to temperature. 
2. Once heat block has come to temperature remove desired western blotting samples from -
80oC freezer and apply lid locking caps to each tube. 
3. Heat samples in heat block for 10 minutes.  
4. While samples are heating assemble gel electrophoresis tank. 
5. Remove pre-cast gels from packaging and remove comb and seal on the bottom of the 
gel. 
6. Place gels in interior chamber frame with the short plates facing each other. Note: If 
running one gel use buffer dam. 
7. Secure interior chamber frame clamps around gels. 
8. Fill interior chamber with 1x Running buffer. 
9. Once samples are finished heating remove from heat block and vortex each sample. Note: 
Never remove lid locking caps while samples are still hot. 
10. Remove protein marker standard from -20oC freezer and allow to come to room 
temperature. 
11. Using gel loading tips and micro-pipette, pipette 3ul of protein marker standard into one 
of the wells. Then 15ul of your sample into an empty well, repeat until all samples have been 
loaded in their own well or no more empty wells are left. 
12. Place interior chamber with newly loaded gels inside the electrophoresis tank. Ensure you 
match the black electrode with the black mark on the tank and the red electrode with the red 
mark on the tank.  
13. Fill the electrophoresis tank with 1x Running buffer to the appropriate level for the 
number of gels. Note: if running only one gel fill tank to the 2 gel mark, if running 3 gels fill 
tank to the 4 gel mark. 
14. Attach the lid of the electrophoresis tank ensure the black electrode is connected to the 
black cable and the red electrode is connected to the red cable. 
15. Plug cables into power pack ensuring that the black cable is attached to the black outlet 
and the red cable is attached to the red outlet. 
16. Set the power pack to maintain constant voltage and set to 200V. 
17. Press the run button. The gel should take about 45 minutes to run, but this could vary 
based on percentage of gel. Once the blue marker dye runs out of the bottom of the gel 
discontinue the run and begin the transfer process. 
18. To begin the Transfer process tank a gel electrophoresis tank place a small stir bar at the 
bottom of the tank and place a red/black transfer chassis into the tank. Ensure the red side of the 
transfer chassis is matched up with the red mark on the tank and the black side of the transfer 
chassis is matched to the black mark on the tank. 




a) Open a clear/black transfer sandwich using the black side as the bottom of the 
sandwich. 
b) Saturate a transfer sponge in 1x Transfer buffer and place it on the black side of 
the transfer sandwich. 
c) Next, saturate a sheet of filter paper in 1x Transfer buffer and place on top of 
transfer sponge. 
d) Break open plastic gel cassette using gel cassette tool and cut-off gel lane dividers 
with gel knife. Float gel in 1x Transfer buffer to remove from plastic cassette. Note: this 
may require gently using the gel knife to break the gel free from plastic cassette. Place 
gel on-top-of saturated filter paper in the transfer sandwich. 
e)  Wet blotting paper in methanol to activate blotting paper, then equilibrate in 1x 
Transfer buffer for 1-2 minutes. Note: prepping the blotting paper can be done prior to 
assembly of sandwich. Place blotting paper on-top-of the gel in the transfer sandwich. 
f) Ensure there are no bubbles between the gel and blotting paper. If bubble are 
present smooth them out. 
g) Saturate a 2nd sheet of filter paper in 1x Transfer buffer and place on-top-of 
blotting paper in the transfer sandwich. 
h) Lastly, Saturate a 2nd transfer sponge in 1x Transfer buffer and place on-top-of 2nd 
sheet of filter paper in the transfer sandwich. 
i) Close and lock transfer sandwich. 
j) Repeat until all gels are in transfer sandwiches. 
20. Place newly assembled transfer sandwich in transfer chassis. Ensure the black side of the 
transfer sandwich faces the black side of the transfer chassis and the clear side of the transfer 
sandwich faces the red side of the transfer chassis.  
21. Place ice pack into electrophoresis tank and fill tank to blotting level with refrigerated 1x 
Transfer buffer.  
22. Place gel electrophoresis tank on stir plate and turn stir plate on. 
23. Attach the lid of the electrophoresis tank ensure the black electrode is connected to the 
black cable and the red electrode is connected to the red cable. 
24. Plug cables into power pack ensuring that the black cable is attached to the black outlet 
and the red cable is attached to the red outlet. 
25. Set the power pack to maintain constant voltage and set to 100V. 
26. Set the power pack timer to 60 minutes and press the run button. 
27. After 1hour, turn off the power supply and remove the blotting paper from the transfer 
sandwich. 
28. Place blotting paper, with the side that was in contact with the gel facing up, in a plastic 
blot washing container. 




30. To block: pour ~10ml of 5% milk in TBST into blot washing container. Place on rocker 
for 1 hour at room temperature. Note: If you need to block longer than an hour place blot 
washing container on a rocker in 4oC. 
31. Prepare primary antibody 
a) Dilute primary antibody to 1:1000 in 1x TBST 
32. After blot has blocked for at least 1 hour, rinse blot 2 times in 1x TBST. 
33. Then wash blot for 5 minutes in 1x TBST at room temperature using a rocker. 
34. Drain off TBST. 
35. Pour ~5 ml of diluted primary antibody on blot and place on a rocker in 4oC refrigerator 
overnight. 
36. After the blot as probed overnight, pour off primary antibody. 
37. Rinse blot twice in 1x TBST, then wash for 10 minutes in 1x TBST at room temperature. 
38. Prep secondary antibody 
a) Dilute secondary antibody to 1:1000 in 1xTBST 
b) Add marker conjugate at 1:20000 to secondary antibody mixture. 
39. Drain off TBST. 
40. Pour ~5 ml of diluted secondary antibody mixture on blot and place on rocker for 1 hour 
at room temperature. 
41. After 1 hour pour off secondary antibody mixture. 
42. Rinse blot twice in 1x TBST 
43. Perform at least 2-3 ten minute washes in 1x TBST 
44. Drain off TBST 
45. Pour 4ml of mixed ECL on blot and rock at room temperature for 2 minutes. 
Alternatively, if running low on ECL place blot on a flat surface that can be placed in imager. 
Then pipette 600ul of mixed ECL on the area of the blot where the bands you probed for are (use 
the colored marker as a guide). Let the blot set for 1 minute. Next, flip the blot over and let it set 
for 1 more minute. Flip blot back over. 






Harsh Striping Protocol 
1. Rinse blot in methanol 
2. Rinse blot 2x in pH2O 
3. Wash blot for 5 minutes in 1xTBST 
4. Drain off TBST 
5. Add a thin layer of Harsh Stripping Buffer to blot 
6. Incubate blot for 30 minutes at room temperature 
7. Drain off Harsh Stripping Buffer 
8. Rinse blot 3x in pH2O 
9. Rinse blot 4x in 1xTBST 
10. Wash blot for 10 minutes in 1xTBST 
11. Repeat western blotting steps 26-42 
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Appendix D: 
IACUC approval 
 
 
 
